Related Experiment Videos
Rapid decrease in high titer of factor VIII inhibitors upon immunosuppressive treatment in severe postpartum acquired
Vlatko Pejsa1, Ivica Grgurević, Rajko Kusec
1Department of Internal Medicine, Dubrava University Hospital, Zagreb, Croatia. vpejsa@kbd.hr
Croatian Medical Journal
|April 23, 2004
Summary
This case study highlights a rapid, successful treatment for postpartum acquired hemophilia using immunosuppressive therapy, achieving remission in just 15 days. The patient experienced no recurrence during subsequent pregnancies.
Area of Science:
- Hematology
- Immunology
- Obstetrics
Background:
- Acquired hemophilia, a rare autoimmune disorder, can develop postpartum due to factor VIII inhibitors.
- This condition presents with severe spontaneous bleeding, posing significant risks to patients.
Observation:
- A 25-year-old woman developed severe bleeding and hematomas post-delivery, diagnosed as acquired hemophilia with high factor VIII inhibitor titers.
- Initial treatment involved blood products and immunosuppressants, including methylprednisolone and cyclophosphamide.
Findings:
- The patient achieved rapid remission within 15 days, with normalized factor VIII activity and APTT, and disappearance of inhibitors.
- This represents the shortest reported remission time for postpartum acquired hemophilia.
- A transient reappearance of inhibitors 10 months later responded promptly to the same therapy.
Implications:
- Early and aggressive immunosuppressive therapy is crucial for managing postpartum acquired hemophilia.
- This approach can be life-saving, inducing rapid remission and preventing recurrence, even in subsequent pregnancies.